Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase

Michelle N. Ngamelue, Kohei Homma, Oksana Lockridge, Oluwatoyin A. Asojo

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Human butyrylcholinesterase (BChE) has been shown to function as an endogenous scavenger of diverse poisons. BChE is a 340 kDa tetrameric glycoprotein that is present in human serum at a concentration of 5 mg l -1. The well documented therapeutic effects of BChE on cocaine toxicity and organophosphorus agent poisoning has increased the need for effective methods of producing recombinant therapeutic BChE. In order to be therapeutically useful, BChE must have a long circulatory residence time or associate as tetramers. Full-length recombinant BChE produced in Chinese hamster ovary (CHO) cells or human embryonic kidney cells has been shown to associate as monomers, with a shorter circulatory residence time than the naturally occurring tetrameric serum protein. Based on the preceding observation as well as the need to develop novel methodologies to facilitate the mass production of therapeutic recombinant BChE, studies have been initiated to determine the structural basis of tetramer formation. Towards these ends, full-length monomeric recombinant BChE has been crystallized for the first time. A 2.8 Å X-ray structure was solved in space group P4212, with unit-cell parameters a = b = 156, c = 146 Å.

Original languageEnglish (US)
Pages (from-to)723-727
Number of pages5
JournalActa Crystallographica Section F: Structural Biology and Crystallization Communications
Volume63
Issue number9
DOIs
StatePublished - Aug 10 2007

Fingerprint

Butyrylcholinesterase
Crystallization
serums
X-Rays
crystallization
X rays
poisons
ovaries
hamsters
poisoning
kidneys
cells
toxicity
x rays
monomers
methodology
proteins
Organophosphate Poisoning
Poisons
Therapeutic Uses

Keywords

  • BChE
  • Recombinant butyrylcholinesterase
  • Tetramerization domain

ASJC Scopus subject areas

  • Biophysics
  • Structural Biology
  • Biochemistry
  • Genetics
  • Condensed Matter Physics

Cite this

Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase. / Ngamelue, Michelle N.; Homma, Kohei; Lockridge, Oksana; Asojo, Oluwatoyin A.

In: Acta Crystallographica Section F: Structural Biology and Crystallization Communications, Vol. 63, No. 9, 10.08.2007, p. 723-727.

Research output: Contribution to journalArticle

@article{16087826ba4d43d09429cec1cefd8d79,
title = "Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase",
abstract = "Human butyrylcholinesterase (BChE) has been shown to function as an endogenous scavenger of diverse poisons. BChE is a 340 kDa tetrameric glycoprotein that is present in human serum at a concentration of 5 mg l -1. The well documented therapeutic effects of BChE on cocaine toxicity and organophosphorus agent poisoning has increased the need for effective methods of producing recombinant therapeutic BChE. In order to be therapeutically useful, BChE must have a long circulatory residence time or associate as tetramers. Full-length recombinant BChE produced in Chinese hamster ovary (CHO) cells or human embryonic kidney cells has been shown to associate as monomers, with a shorter circulatory residence time than the naturally occurring tetrameric serum protein. Based on the preceding observation as well as the need to develop novel methodologies to facilitate the mass production of therapeutic recombinant BChE, studies have been initiated to determine the structural basis of tetramer formation. Towards these ends, full-length monomeric recombinant BChE has been crystallized for the first time. A 2.8 {\AA} X-ray structure was solved in space group P4212, with unit-cell parameters a = b = 156, c = 146 {\AA}.",
keywords = "BChE, Recombinant butyrylcholinesterase, Tetramerization domain",
author = "Ngamelue, {Michelle N.} and Kohei Homma and Oksana Lockridge and Asojo, {Oluwatoyin A.}",
year = "2007",
month = "8",
day = "10",
doi = "10.1107/S1744309107037335",
language = "English (US)",
volume = "63",
pages = "723--727",
journal = "Acta Crystallographica Section F:Structural Biology Communications",
issn = "1744-3091",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase

AU - Ngamelue, Michelle N.

AU - Homma, Kohei

AU - Lockridge, Oksana

AU - Asojo, Oluwatoyin A.

PY - 2007/8/10

Y1 - 2007/8/10

N2 - Human butyrylcholinesterase (BChE) has been shown to function as an endogenous scavenger of diverse poisons. BChE is a 340 kDa tetrameric glycoprotein that is present in human serum at a concentration of 5 mg l -1. The well documented therapeutic effects of BChE on cocaine toxicity and organophosphorus agent poisoning has increased the need for effective methods of producing recombinant therapeutic BChE. In order to be therapeutically useful, BChE must have a long circulatory residence time or associate as tetramers. Full-length recombinant BChE produced in Chinese hamster ovary (CHO) cells or human embryonic kidney cells has been shown to associate as monomers, with a shorter circulatory residence time than the naturally occurring tetrameric serum protein. Based on the preceding observation as well as the need to develop novel methodologies to facilitate the mass production of therapeutic recombinant BChE, studies have been initiated to determine the structural basis of tetramer formation. Towards these ends, full-length monomeric recombinant BChE has been crystallized for the first time. A 2.8 Å X-ray structure was solved in space group P4212, with unit-cell parameters a = b = 156, c = 146 Å.

AB - Human butyrylcholinesterase (BChE) has been shown to function as an endogenous scavenger of diverse poisons. BChE is a 340 kDa tetrameric glycoprotein that is present in human serum at a concentration of 5 mg l -1. The well documented therapeutic effects of BChE on cocaine toxicity and organophosphorus agent poisoning has increased the need for effective methods of producing recombinant therapeutic BChE. In order to be therapeutically useful, BChE must have a long circulatory residence time or associate as tetramers. Full-length recombinant BChE produced in Chinese hamster ovary (CHO) cells or human embryonic kidney cells has been shown to associate as monomers, with a shorter circulatory residence time than the naturally occurring tetrameric serum protein. Based on the preceding observation as well as the need to develop novel methodologies to facilitate the mass production of therapeutic recombinant BChE, studies have been initiated to determine the structural basis of tetramer formation. Towards these ends, full-length monomeric recombinant BChE has been crystallized for the first time. A 2.8 Å X-ray structure was solved in space group P4212, with unit-cell parameters a = b = 156, c = 146 Å.

KW - BChE

KW - Recombinant butyrylcholinesterase

KW - Tetramerization domain

UR - http://www.scopus.com/inward/record.url?scp=34548403883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548403883&partnerID=8YFLogxK

U2 - 10.1107/S1744309107037335

DO - 10.1107/S1744309107037335

M3 - Article

C2 - 17768338

AN - SCOPUS:34548403883

VL - 63

SP - 723

EP - 727

JO - Acta Crystallographica Section F:Structural Biology Communications

JF - Acta Crystallographica Section F:Structural Biology Communications

SN - 1744-3091

IS - 9

ER -